229 related articles for article (PubMed ID: 27301751)
1. Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins.
Wood JP; Baumann Kreuziger LM; Desai UR; Mast AE
Br J Haematol; 2016 Oct; 175(1):123-32. PubMed ID: 27301751
[TBL] [Abstract][Full Text] [Related]
2. Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism.
Buyue Y; Misenheimer TM; Sheehan JP
J Thromb Haemost; 2012 Oct; 10(10):2086-98. PubMed ID: 22905983
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of factor IXa inhibition by antithrombin in the presence of unfractionated and low molecular weight heparins and fucoidan.
Mauray S; de Raucourt E; Talbot JC; Dachary-Prigent J; Jozefowicz M; Fischer AM
Biochim Biophys Acta; 1998 Sep; 1387(1-2):184-94. PubMed ID: 9748565
[TBL] [Abstract][Full Text] [Related]
4. Covalently linking heparin to antithrombin enhances prothrombinase inhibition on activated platelets.
Stevic I; Chan HH; Chander A; Berry LR; Chan AK
Thromb Haemost; 2013 Jun; 109(6):1016-24. PubMed ID: 23494009
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of unfractionated heparin and low-molecular-weight heparins on tissue thromboplastin inhibition test.
Gerbutavicius R; Iqbal O; Messmore H; Hoppensteadt DA; Demir M; Khan E; Bacher P; Fareed J
Clin Appl Thromb Hemost; 2000 Oct; 6(4):190-6. PubMed ID: 11030523
[TBL] [Abstract][Full Text] [Related]
6. Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts.
Matziolis G; Perka C; Disch A; Zippel H
Calcif Tissue Int; 2003 Oct; 73(4):370-9. PubMed ID: 12874702
[TBL] [Abstract][Full Text] [Related]
7. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation.
Linkins LA; Julian JA; Rischke J; Hirsh J; Weitz JI
Thromb Res; 2002 Sep; 107(5):241-4. PubMed ID: 12479885
[TBL] [Abstract][Full Text] [Related]
8. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins.
Bendz B; Hansen JB; Andersen TO; Ostergaard P; Sandset PM
Br J Haematol; 1999 Dec; 107(4):756-62. PubMed ID: 10606880
[TBL] [Abstract][Full Text] [Related]
9. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
Graff J; Picard-Willems B; Harder S
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
[TBL] [Abstract][Full Text] [Related]
10. Histones Differentially Modulate the Anticoagulant and Profibrinolytic Activities of Heparin, Heparin Derivatives, and Dabigatran.
Ammollo CT; Semeraro N; Carratù MR; Colucci M; Semeraro F
J Pharmacol Exp Ther; 2016 Feb; 356(2):305-13. PubMed ID: 26578266
[TBL] [Abstract][Full Text] [Related]
11. Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).
Montalescot G; Bal-dit-Sollier C; Chibedi D; Collet JP; Soulat T; Dalby M; Choussat R; Cohen A; Slama M; Steg PG; Dubois-Randé JL; Metzger JP; Tarragano F; Guermonprez JL; Drouet L;
Am J Cardiol; 2003 Apr; 91(8):925-30. PubMed ID: 12686329
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex.
Stevic I; Chan HH; Berry LR; Chander A; Chan AK
J Biochem; 2013 Jan; 153(1):103-10. PubMed ID: 23100269
[TBL] [Abstract][Full Text] [Related]
13. Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation.
Ben-Hadj-Khalifa S; Hézard N; Almawi WY; Remy MG; Florent B; Mahjoub T; Nguyen P
Blood Coagul Fibrinolysis; 2011 Jul; 22(5):369-73. PubMed ID: 21577096
[TBL] [Abstract][Full Text] [Related]
14. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation.
Gerotziafas GT; Petropoulou AD; Verdy E; Samama MM; Elalamy I
J Thromb Haemost; 2007 May; 5(5):955-62. PubMed ID: 17461929
[TBL] [Abstract][Full Text] [Related]
15. Heparin blunts endotoxin-induced coagulation activation.
Pernerstorfer T; Hollenstein U; Hansen J; Knechtelsdorfer M; Stohlawetz P; Graninger W; Eichler HG; Speiser W; Jilma B
Circulation; 1999 Dec 21-28; 100(25):2485-90. PubMed ID: 10604885
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of inhibition of the prothrombinase complex by a covalent antithrombin-heparin complex.
Stevic I; Berry LR; Chan AK
J Biochem; 2012 Aug; 152(2):139-48. PubMed ID: 22518847
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effects of unfractionated heparin and the low-molecular-weight heparins dalteparin and enoxaparin on spontaneous platelet aggregation and adenosine diphosphate activity in platelets during the third trimester of pregnancy.
Ajayi AA; Pharmacols FB; Cooper J; Horn EH; Rubin PC
Methods Find Exp Clin Pharmacol; 2007 Oct; 29(8):539-45. PubMed ID: 18040530
[TBL] [Abstract][Full Text] [Related]
18. [Determination of sulfation degree of heparin and low molecular weight heparins by capillary electrophoresis].
Shen Y; Kang J
Se Pu; 2020 Oct; 38(10):1238-1242. PubMed ID: 34213122
[TBL] [Abstract][Full Text] [Related]
19. Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase.
Anderson JA; Fredenburgh JC; Stafford AR; Guo YS; Hirsh J; Ghazarossian V; Weitz JI
J Biol Chem; 2001 Mar; 276(13):9755-61. PubMed ID: 11134031
[TBL] [Abstract][Full Text] [Related]
20. In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis.
Kaeberich A; Raaz U; Vogt A; Maedgefessel L; Neuhart E; Krezel C; Drouget L; Hauroeder B; Buerke M; Werdan K; Schlitt A
J Thromb Thrombolysis; 2014; 37(2):118-30. PubMed ID: 23821043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
